Posts for category: Recent News

AgeneBio Announces Additional Funding to Advance Novel GABA-A Therapeutic Program to Address Alzheimer’s and Other CNS Conditions

AgeneBio today announced it has received significant additional resources to accelerate the development of their GABA-A a5 Positive Allosteric Modulation (PAM), a novel approach to mild cognitive impairment (MCI) due to Alzheimer's Disease (AD) that targets hippocampal overactivity that leads to degeneration and cognitive decline in patients with MCI due to AD, autism and schizophrenia.

T.J. Oshie and Dr. Michela Gallagher Honored at Ninth Annual Great Ladies Luncheon

Dr. Michela Gallagher, founder and CEO of AgeneBio, Inc. and professor at Johns Hopkins University, was honored at the luncheon for her work advancing treatments for Alzheimer's disease. Dr. Gallagher received the inaugural Estelle Gelman Award for Innovation in Drug Discovery for her groundbreaking research that holds the potential to yield the first drug to slow the progression of symptoms associated with mild cognitive impairment due to Alzheimer's disease.

AgeneBio Believes a Switch in Research Strategy Can Make Alzheimer’s Preventable

Michela Gallagher, CEO of AgeneBio, and her staff have given themselves a big challenge – to develop the first and only therapeutic targeting brain network imbalance and potentially the first therapeutic to slow progression to and delay the onset of Alzheimer’s dementia, which is becoming a public health crisis. Gallagher believes the biggest roadblock to finding…

AgeneBio Announces First Patient Enrollment in the Phase 3 Clinical Trial to Evaluate AGB101 to Treat Amnestic Mild Cognitive Impairment Due to Alzheimer’s Disease

AGB101 is the first investigational therapeutic that targets the reduction of hippocampal overactivity. The study evaluates both Primary and Secondary Endpoints to measure cognitive and functional efficacy. Secondary imaging endpoints will include measures of neurodegeneration. BALTIMORE, MD (January 17, 2019) – AgeneBio announced today that it has enrolled its first patient in a Phase 3…

AgeneBio Announces Two NIH Grant Awards to Advance its Therapeutic Pipeline to Combat Progression of Alzheimer’s Disease

– NIH awards an expected $16 million to support Phase 3 pivotal clinical trial of AGB-101, a once-a-day treatment to slow progression in Mild Cognitive Impairment due to Alzheimer’s disease. – NIH awards follow on funding from the Blueprint Neurotherapeutics (BPN) Network Program to support development of GABA-A a5 small molecule program targeting hippocampal overactivity.…

AgeneBio Founder Dr. Michela Gallagher participates in the 2018 Milken Global Conference

Gallagher highlights the groundbreaking clinical trial, HOPE4MCI, which could slow progression from Mild Cognitive Impairment to Alzheimer’s dementia LOS ANGELES, April 30, 2018 — Today, AgeneBio Founder Dr. Michela Gallagher participated in a panel discussion at the Milken Global Conference Alzheimer’s Disease: Rewriting the Playbook. The panel, hosted by Milken’s LaTese Briggs and including Todd Rainwater of the Rainwater Charitable Foundation, Lauren Miller Rogan of Hilarity…

AgeneBio to Speak at ASENT 2018 Annual Meeting

Emerging Therapeutics Focus on Hippocampal Hyperactivity in Patients with Mild Cognitive Impairment Due to Alzheimer’s Disease Baltimore, MD, February 28, 2018 — AgeneBio, a pharmaceutical company developing innovative therapeutics for unserved patients battling neurodegeneration, today announced that founder and Chief Scientific Officer, and Krieger-Eisenhower Professor of Psychological and Brain Sciences at Johns Hopkins University, Michela…

AgeneBio Founder Michela Gallagher to Speak at 2018 NIH Alzheimer’s Research Summit

Focus on Research Targeting Hippocampal Hyperactivity in Patients with Mild Cognitive Impairment Due to Alzheimer’s Disease Baltimore, MD, February 28, 2018 — AgeneBio, a pharmaceutical company developing innovative therapeutics for unserved patients battling neurodegeneration, today announced that founder and Chief Scientific Officer, HOPE4MCI Principal Investigator, and Krieger-Eisenhower Professor of Psychological and Brain Sciences at Johns…